Pharmaceuticals, Biotechnology & Life Sciences

WuXi AppTec’s 2025 earnings lift shares, showing 52% EBITDA growth and a 33% 2026 revenue outlook driven by mRNA, gene‑editing and oncology CRO services.

FDA removes suicide‑risk warning from Eli Lilly’s GLP‑1 weight‑loss drugs, simplifying prescribing, boosting patient confidence, and strengthening brand trust.

IQVIA Holdings Inc. boosts earnings with AI‑driven market‑access tools and growing clinical‑trial services, targeting a 45% market share and $1.2 bn 2024 revenue.

Shionogi & Co.: Japan’s quietly stable pharma firm prioritises long‑term R&D, low leverage, and PMDA‑friendly compliance—offering a value‑investor‑friendly platform for future breakthroughs.

Regeneron’s mixed analyst reviews, strong Eylea®/Dupixent® sales growth, and promising Apogee pipeline reveal cautious optimism and future upside for investors.

Thermo Fisher’s new TetraScience and NVIDIA AI collaborations boost lab‑to‑cloud data, slash costs and drive 4‑5% revenue lift, positioning the company ahead of patent cliffs and competitor AI race.

Argenx’s VYVGART gains FDA priority‑review for seronegative generalized myasthenia gravis, offering early, evidence‑based hope for a rare, underserved patient group.

Novartis reaffirms its acquisition strategy, focusing on disciplined capital allocation and portfolio growth in oncology, immunology and ophthalmology to navigate a competitive, regulated pharma landscape.

Merck’s aggressive 2030 growth plan focuses on fast‑trailing oncology launches, patent‑cliff safeguards, and multi‑billion‑dollar acquisitions to boost revenue and shareholder returns.

Galderma’s Canadian approval of Nemluvio, an IL‑23 biologic for atopic dermatitis, marks a first‑mover move that could offset patent cliffs and boost specialty dermatology revenue.